VALBIOTIS: Growth and Reinforced Strategy in the First Half of 2026

Valbiotis SA has released its results for the first half of 2026, marked by significant expansion. Revenue reached €0.8 million, a 130% increase compared to the previous year. This growth resulted from an increase in both the number of customers and average sales in pharmacies and online. The strengthening of the sales structure in France and internationally, including a joint venture in China, supported this momentum.

Operating expenses remain under control, rising by 8%. Sales and marketing expenses increased by 16% to support this growth. The company posted a net loss of €3.4 million, an improvement compared to a projected loss of €4.6 million in 2025. Cash reserves, bolstered by a capital increase, ensure financial viability until the end of 2027.